9 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
−Removed: Amendment No.2 to the Collaboration Agreement by and between Astellas Pharma, Inc.
−Removed: and FibroGen, Inc., dated as of June 6, 2025.
−Removed: Second Amendment to Financing Agreement, by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of June 5, 2025.
−Removed: Third Amendment to Financing Agreement, by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of July 14, 2025.
+Added: Amendment No.2 to Second Amended and Restated Exclusive License Agreement, by and among Eluminex Biosciences (Suzhou) Limited, FibroGen, Inc., FibroGen International (Hong Kong) Limited, FibroGen (China) Medical Technology Development Co., Ltd., and Beijing Falikang Pharmaceutical Co., Ltd., dated as of August 5, 2025 .
+Added: Termination Agreement, by and between, FibroGen, Inc.
+Added: and AstraZeneca AB, effective as of February 25, 2024, as amended and restated on August 29, 2025.
+Added: Amendment to Share Purchase Agreement, by and among AstraZeneca Treasury Limited, FibroGen China Anemia Holdings, Ltd., and FibroGen, Inc., dated as of August 29, 2025.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
10 unchanged sentences
FibroGen, Inc.
−Removed: August 11, 2025
+Added: November 10, 2025
/s/ Thane Wettig
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 11, 2025
+Added: November 10, 2025
/s/ David DeLucia
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.